Trial results

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119 on ClinicalTrials.gov · last registry update 2022-03-28

Stopped early, having planned 241 participants. The sponsor logged completion for 7 January 2019. Primary outcome, as filed: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

TERMINATED

Phase

P3

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

241

Started

2018-02-20

Primary completion

2019-01-07 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.